The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JE, ABMD and SRPT

The Klein Law Firm


The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JE, ABMD and SRPT

Friday, September 20, 2019 3:20 PM

NEW YORK, NY / ACCESSWIRE / September 20, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Just Energy Group Inc. (NYSE:JE)
Class Period: November 9, 2017 to August 19, 2019
Lead Plaintiff Deadline: September 30, 2019

The lawsuit alleges that throughout the class period, Just Energy Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company experienced customer enrollment and nonpayment issues; (2) as a result, the Company was reasonably likely to incur an impairment charge to its accounts receivable; (3) as a result, the Company lacked adequate internal control over its financial reporting; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in JE: http://www.kleinstocklaw.com/pslra-1/just-energy-group-inc-loss-submission-form?id=3625&from=1.

Abiomed, Inc. (NASDAQGS:ABMD)
Class Period: January 31, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 7, 2019

The complaint alleges that during the class period Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed's revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ABMD: http://www.kleinstocklaw.com/pslra-1/abiomed-inc-loss-submission-form?id=3625&from=1.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Class Period: September 6, 2017 to August 19, 2019
Lead Plaintiff Deadline: October 29, 2019

The complaint alleges that throughout the class period Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SRPT: http://www.kleinstocklaw.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?id=3625&from=1.

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm


SHARE ARTICLE